Source: International Congress 2018 – New biologics for asthma: which patients, which agents, which results, at what cost?
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
E. Bel (Amsterdam, Netherlands). At the interface: the translational science supporting the clinical use of anti-cytokine therapy. International Congress 2018 – New biologics for asthma: which patients, which agents, which results, at what cost?

Member's Comments

No comment yet.

Related content which might interest you: Biologics: current use and future applications for personalised therapy Source: Virtual Congress 2021 – Wheezing illnesses along the life span Year: 2021 Clinical use of new and repurposed drugs: the role and contribution of the ERS collaborative projects Source: International Congress 2017 – In the frontline of the fight against tuberculosis Year: 2017 Anti-IgE therapy: current knowledge and future perspective Source: International Congress 2019 – The journey towards personalized medicine in asthma: where are we now? Year: 2019 Clinical trial landscape for M/XDR-TB: current evidence and future perspectives Source: International Congress 2019 – Recent developments and future perspectives in the diagnosis and treatment of tuberculosis Year: 2019 How to accelerate bringing new drugs to patients: role of clinical trials networks Source: International Congress 2019 – Rare lung diseases Year: 2019 Human translational medicine in ILD: the promise of new drugs Source: Research Seminar 2014 - Human translational medicine: a key bridge for the development of new drugs for severe asthma, COPD and ILD Year: 2014 How to stop LC-fILD progression: an overview of modern therapeutic strategies Source: Virtual Congress 2021 – Lung cancer and fibrotic interstitial lung diseases: a challenging association for pulmonologists Year: 2021 The new Back to Basics section: emerging concepts in basic and translational medicine Source: Eur Respir J 2014; 44: 297-298 Year: 2014 Advances in targeted therapy: the clinicians point of view Source: International Congress 2014 – Update on lung cancer biology for clinicians Year: 2014 New and future developments of therapy for asthma in children Source: Eur Respir Mon 2012; 56: 224-234 Year: 2012 Anti-IgE therapy: rationale and clinical evidence Source: Annual Congress 2007 - Changing practice with anti-IgE: patient, physician and payor perspectives Year: 2007 New clinical research strategies in thoracic oncology: clinical trial design, adaptive, basket and umbrella trials, new end-points and new evaluations of response Source: Eur Respir Rev 2014; 23: 367-378 Year: 2014 What next? Basic research, new treatments and a patient-centred approach in controlling tuberculosis Source: Eur Respir Monogr 2018; 82: 414-429 Year: 2018 Clinical implications and opportunities for new drug therapies Source: Annual Congress 2008 - Deadly networks: disease-causing protein and DNA modifications Year: 2008 The concept of control in COPD: a new proposal for optimising therapy Source: Eur Respir J 2014; 44: 1072-1075 Year: 2014 Getting approval for new therapeutic medical devices versus drugs: are the differences justified? Source: Eur Respir Rev 2016; 25: 223-226 Year: 2016